에 대한 최신 뉴스 Cerus (NASDAQ:CERS) 주식

Cerus

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Equities

News

Markets

ETFs

AMZN

ARKQ

CERS

월요일에 캐시 우드가 이끄는 아크 인베스트가 아마존닷컴(NASDAQ:AMZN)의 주식을 대량 매수하는 중요한 결정을 내렸다. 이는 최근 아마존이 증가하는 에너지 수요를 충족하기 위해 원자력 에너지에 대한 관심을 높이고 있을 가능성이 제기된 가운데 발생한 일이다.

아크 인베스트가 원자력 에너지에 대한 관심 증가로 아마존 주식 395만 달러 규모 매입

Cerus Corp

Preliminary Full-Year 2024 Product Revenues Total $180.3 million, 15% Over 2023 Results and Exceed Prior Product Revenue Guidance
2025 Product Revenues Expected to be Between $194-$200 million, Reflecting 8%-11% Growth Year-Over-Year
Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for full-year 2025.
The Company expects its preliminary full-year 2024 product revenue to be $180.3 million, exceeding the Company's 2024 product revenue guidance range of $177-$179 million. Included in the full-year preliminary 2024 product revenue results were $9.2 million of IFC revenue, representing growth of 42% over 2023 results. These preliminary product revenue results have not been audited and are therefore subject to change.
"We are pleased with our strong performance, which contributed to continued double-digit product revenue growth for the full year 2024, driven by sustained momentum across our INTERCEPT platelet franchise both in the U.S. and internationally and importantly, from our IFC business, which continues to gain momentum," said William "Obi" Greenman, president and chief executive officer of Cerus. "As we look ahead to 2025, we are excited to build on this success through disciplined execution, continued growth in the platelet and IFC franchises, and the advancement of our pipeline, including the planned upcoming LED Illuminator launch in Europe, as well as anticipated further geographic expansion."
The Company expects full-year 2025 product revenue will be in the range of $194-$200 million, of which IFC is expected to be in the range of $12-$15 million. Year-over-year product revenue growth for the first quarter of 2025 is expected to be approximately 10% to 15% over the first quarter of 2024.

Biotech

Guidance

Global

General

Cerus Announces Preliminary 2024 Revenues Of $180.3M, Up 15% From 2023; 2025 Revenue Projected At $194M-$200M, Indicating 8%-11% Growth; IFC Revenue Grows 42% In 2024; 2025 IFC Revenue Predicted Between $12M-$15M; Anticipates LED Illuminator Launch In Europe

WIIM

Cerus shares are trading lower after the company reported mixed Q3 financial results.

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) raises FY2024 sales outlook from $172.00 million-175.00 million to $177.00 million-179.00 million.

Cerus Raises FY2024 Product Revenue Guidance to $177.00M-179.00M  VS Est. 189.86M

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $46.017 million which missed the analyst consensus estimate of $47.335 million by 2.78 percent. This is a 15.70 percent increase over sales of $39.772 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Cerus Q3 2024 GAAP EPS $(0.02) Beats $(0.03) Estimate, Sales $46.017M Miss $47.335M Estimate

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Cerus to report an earnings per share (EPS) of $-0.03.
Anticipation surrounds Cerus's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 14.95% increase in the share price the following trading session.
Here's a look at Cerus's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.05</td>
<td>-0.01</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>15.0%</td>
<td>-8.0%</td>
<td>22.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730221292_0_0.png" alt="eps graph" />
<h3>Insights Shared by Analysts on Cerus</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Cerus.
Cerus has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $3.0, the consensus suggests a potential 74.42% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of OraSure Technologies, Rockwell Medical and TELA Bio, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, OraSure Technologies is favoring an Neutral trajectory, with an average 1-year price target of $5.0, suggesting a potential 190.7% upside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Rockwell Medical, with an average 1-year price target of $9.0, indicating a potential 423.26% upside.</li>
<li>For TELA Bio, analysts project an Buy trajectory, with an average 1-year price target of $10.4, indicating a potential 504.65% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
In the peer analysis summary, key metrics for OraSure Technologies, Rockwell Medical and TELA Bio are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerus</td>
<td>Buy</td>
<td>16.02%</td>
<td>$24.67M</td>
<td>-11.68%</td>
</tr>
<tr>
<td>OraSure Technologies</td>
<td>Neutral</td>
<td>-36.41%</td>
<td>$24.69M</td>
<td>-0.14%</td>
</tr>
<tr>
<td>Rockwell Medical</td>
<td>Buy</td>
<td>42.88%</td>
<td>$4.55M</td>
<td>1.55%</td>
</tr>
<tr>
<td>TELA Bio</td>
<td>Buy</td>
<td>11.02%</td>
<td>$11.07M</td>
<td>-146.05%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Cerus ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit. For Return on Equity, Cerus is in the middle compared to its peers.
<h3>Unveiling the Story Behind Cerus</h3>
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
<h3>Breaking Down Cerus's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Cerus displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 16.02%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Cerus's net margin excels beyond industry benchmarks, reaching -12.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cerus's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -11.68%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Cerus's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.08%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 1.99, Cerus faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/CERS/earnings">To track all earnings releases for Cerus visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cerus's Earnings: A Preview

On Monday, Cathie Wood-led Ark Invest made a significant move by purchasing shares of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). This comes amidst recent developments suggesting that Amazon may be ramping up its interest in nuclear energy to fuel its growing needs.
The Amazon Trade
Ark Invest&#8217;s ARK Autonomous Technology &amp; Robotics ETF (BAYS: ARKQ) fund purchased 20,883 shares of Amazon, reflecting 0.4951% of the ETF. At the closing price of $189.07 on the same day, the value of the trade amounts to approximately $3.95 million. This move follows a series of recent developments around Amazon&#8217;s potential foray into nuclear energy.
A Benzinga report, in September, revealed that Amazon had <a href="https://www.benzinga.com/markets/equities/24/09/40969515/amazon-going-nuclear-hiring-plans-indicate-company-may-be-eyeing-nuclear-to-meet-energy-needs">reposted a job opening</a> for a Principal Nuclear Engineer in its Data Center Engineering division, raising questions about its long-term energy strategy. Additionally, Amazon announced the expansion of its collaboration with Intel Corp., which has also <a href="https://www.benzinga.com/news/large-cap/24/09/40904271/whats-going-on-with-amazon-stock">positively impacted its stock.</a>
Wood&#8217;s confidence in Amazon has sparked a debate on whether this is a signal of the tech giant&#8217;s impending turnaround or another <a href="https://www.benzinga.com/news/24/10/41247558/cathie-woods-amazon-bet-from-kiss-of-death-to-bold-investment-is-she-right-this-time">high-risk gamble</a>.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41308908/man-who-accidentally-threw-hard-drive-containing-8-000-bitcoins-worth-half-a-billion-dolla?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Man Who Accidentally Threw Hard Drive Containing 8,000 Bitcoins Worth Half A Billion Dollars In Landfill Sues Local City Council For Not Excavating The Site</a>
Other Key Trades: 
Ark Invest&#8217;s ARKG and ARKK funds bought shares of CRISPR Therapeutics AG (CRSP) and Cerus Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>).
ARKQ sold a significant number of shares of Oklo Inc (OKLO) while buying shares of BWX Technologies Inc (BWXT) and 3D Systems Corp ( DDD). Shares of Materialise NV (MTLS) and Markforged Holding Corp (MKFG) were sold by the ARKQ and ARKX funds.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41422633/investors-lost-over-95-of-their-wealth-in-this-nvidia-linked-etf-while-jensen-huang-led-chip-gia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Investors Lost Over 95% Of Their Wealth In This Nvidia-Linked ETF While Jensen Huang-Led Chip Giant Gained 220% In The Past Year: Here&#8217;s More</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Cathie Wood's Ark Invest Buys $3.95M Worth Of Amazon Stock Amid Company's Nuclear Moves

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 recording gains on Thursday.
The Dow traded up 0.24% to 43,179.49 while the NASDAQ rose 0.24% to 18,411.77. The S&amp;P 500 also rose, gaining, 0.08% to 5,847.03.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Information technology shares jumped by 0.8% on Thursday.
In trading on Thursday, communication services shares fell by 0.7%.
Top Headline
U.S. crude oil inventories declined by 2.192 million barrels in the week ended Oct. 11, versus estimates of a 2.3 million gain, the EIA said.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) shares shot up 18% to $2.6650 after the company announced it secured a DOE conditional commitment loan of $1.46 billion for its net-zero 1 sustainable aviation fuel plant in South Dakota.</li>
<li>Shares of Nixxy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) got a boost, surging 52% to $3.6010 after the company provided updates on the business including its acquisition strategy in traditional markets and enhancing operations through technology and data analytics.</li>
<li>Iridium Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) shares were also up, gaining 12% to $33.97 after the company reported better-than-expected third-quarter revenue results and raised its FY24 OEBITDA guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Proficient Auto Logistics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) shares dropped 28% to $10.10 after the company announced it expects its third-quarter net income to be significantly degraded due to a reduced level of revenue and resulting loss of operating leverage. Also, the company said it expects that the Longshoremen strike could have negatively impacted unit volumes during the fourth quarter and beyond.</li>
<li>Shares of Cerus Corporation. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) were down 18% to $1.4750 after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) was down, falling 16% to $2.75 after the company announced the pricing of an offering and corresponding investment from an affiliate of the Public Investment Fund (PIF).</li>
</ul>
Commodities In commodity news, oil traded down 0.3% to $70.19 while gold traded up 0.7% at $2,709.00.
Silver traded down 0.5% to $31.83 on Thursday, while copper fell 0.9% to $4.3270.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 gained 0.83%, Germany's DAX rose 0.77% and France's CAC 40 climbed 1.22%. Spain's IBEX 35 Index fell 0.77%, while London's FTSE 100 gained 0.67%.
The European Central Bank cut its three key interest rates by 25 bps in October. Annual inflation rate in the Eurozone fell to 1.7% in September versus initial estimates of 1.8% and compared to 2.2% in August.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 1.02%, China's Shanghai Composite Index dipping 1.05% and India's BSE Sensex falling 0.61%.
Economics
<ul>
<li>Industrial production in the U.S. declined 0.3% from a month ago in September.</li>
<li>U.S. initial jobless claims fell by 19,000 in the week ending Oct. 12.</li>
<li>The Philadelphia Fed Manufacturing Index climbed to 10.3 in October compared to 1.7 in September and topping market estimates of 3.</li>
<li>U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise.</li>
<li>Total business inventories increased by 0.3% month-over-month in August.</li>
<li>The NAHB/Wells Fargo Housing Market Index climbed to 43 in October from 41 in the prior month.</li>
<li>U.S. natural-gas stocks increased 76 billion cubic feet during the week ended Oct. 11, compared to market estimates of a 78 billion cubic feet gain.</li>
<li>U.S. crude oil inventories declined by 2.192 million barrels in the week ended Oct. 11, versus estimates of a 2.3 million gain, the EIA said.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41377581/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel"> Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Trading Ideas

GEVO

IRDM

LCID

NIXX

S&P 5000 Edges Higher; US Crude Oil Inventories Fall

Cerus shares are trading lower after Stifel cut its price target on the stock from $6 to $3.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.5% on Thursday.
The Dow traded up 0.28% to 43,199.12 while the NASDAQ rose 0.53% to 18,464.23. The S&amp;P 500 also rose, gaining, 0.30% to 5,860.00.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Information technology shares jumped by 1.1% on Thursday.
In trading on Thursday, real estate shares fell by 0.6%.
Top Headline
U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) shares shot up 18% to $2.6450 after the company announced it secured a DOE conditional commitment loan of $1.46 billion for its net-zero 1 sustainable aviation fuel plant in South Dakota.</li>
<li>Shares of Nixxy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) got a boost, surging 116% to $5.12 after the company provided updates on the business including its acquisition strategy in traditional markets and enhancing operations through technology and data analytics.</li>
<li>Iridium Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) shares were also up, gaining 16% to $35.11 after the company reported better-than-expected third-quarter revenue results and raised its FY24 OEBITDA guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Proficient Auto Logistics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) shares dropped 23% to $10.68 after the company announced it expects its third-quarter net income to be significantly degraded due to a reduced level of revenue and resulting loss of operating leverage. Also, the company said it expects that the Longshoremen strike could have negatively impacted unit volumes during the fourth quarter and beyond.</li>
<li>Shares of Cerus Corporation. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) were down 20% to $1.4486 after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) was down, falling 15% to $2.7950 after the company announced the pricing of an offering and corresponding investment from an affiliate of the Public Investment Fund (PIF).</li>
</ul>
Commodities In commodity news, oil traded up 0.5% to $70.76 while gold traded up 0.6% at $2,706.20.
Silver traded down 0.2% to $31.91 on Thursday, while copper fell 0.6% to $4.3435.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.8%, Germany's DAX rose 0.60% and France's CAC 40 climbed 1.23%. Spain's IBEX 35 Index fell 0.6%, while London's FTSE 100 gained 0.56%.
The European Central Bank cut its three key interest rates by 25 bps in October. Annual inflation rate in the Eurozone fell to 1.7% in September versus initial estimates of 1.8% and compared to 2.2% in August.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 1.02%, China's Shanghai Composite Index dipping 1.05% and India's BSE Sensex falling 0.61%.
Economics
<ul>
<li>Industrial production in the U.S. declined 0.3% from a month ago in September.</li>
<li>U.S. initial jobless claims fell by 19,000 in the week ending Oct. 12.</li>
<li>The Philadelphia Fed Manufacturing Index climbed to 10.3 in October compared to 1.7 in September and topping market estimates of 3.</li>
<li>U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise.</li>
<li>Total business inventories increased by 0.3% month-over-month in August.</li>
<li>The NAHB/Wells Fargo Housing Market Index climbed to 43 in October from 41 in the prior month.</li>
<li>U.S. natural-gas stocks increased 76 billion cubic feet during the week ended Oct. 11, compared to market estimates of a 78 billion cubic feet gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41377581/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel"> Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Crude Oil Edges Higher; US Retail Sales Top Expectations

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares increased by 109.6% to $2.18 during Thursday's regular session. The company's market cap stands at $371.9 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock increased by 61.42% to $0.52. The market value of their outstanding shares is at $3.4 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock increased by 37.97% to $0.46. The company's market cap stands at $13.7 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock rose 36.93% to $1.14. The company's market cap stands at $19.3 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock increased by 27.16% to $6.46. The company's market cap stands at $33.6 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock increased by 25.11% to $0.46. The market value of their outstanding shares is at $74.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock declined by 33.9% to $5.55 during Thursday's regular session. The market value of their outstanding shares is at $80.5 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 31.23% to $4.45. The company's market cap stands at $4.5 million. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) stock fell 19.67% to $2.67. The market value of their outstanding shares is at $107.6 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined by 18.24% to $1.47. The market value of their outstanding shares is at $272.7 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock fell 15.52% to $0.79. The company's market cap stands at $123.2 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares decreased by 14.99% to $0.67. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATNF

BDRX

KZIA

MTEM

PIII

QNRX

RENB

SONN

TLPH

TVGN

VSTM

12 Health Care Stocks Moving In Thursday's Intraday Session

Stifel analyst Mathew Blackman maintains Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) with a Buy and lowers the price target from $6 to $3.

Price Target

Analyst Ratings

Stifel Maintains Buy on Cerus, Lowers Price Target to $3

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.
Shares of CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41369567/csx-stock-falls-after-worse-than-expected-q3-results-details">third-quarter earnings below analyst estimates.</a>
CSX reported quarterly GAAP earnings of 46 cents per share, which missed the consensus estimate of 48 cents per share. Quarterly revenue came in at $3.62 billion, also missing the consensus estimate of $3.676 billion. The company said its total volume of 1.59 million units for the quarter was 3% higher as compared to the third quarter of 2023.
CSX shares dipped 5.4% to $33.55 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares dipped 16.2% to $3.37 in pre-market trading after surging 122% on Wednesday.</li>
<li>Lucid Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) declined 14.6% to $2.80 in pre-market trading after the company announced a public offering of common stock, along with a corresponding investment by an affiliate of the Public Investment Fund.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares fell 13.2% to $0.6350 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares fell 10.6% to $18.33 in pre-market trading. The company commenced its public offering of common stock.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares fell 8.8% to $1.64 in pre-market trading after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>KE Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NASDAQ">BEKE</a>) shares declined 7.7% to $20.23 in pre-market trading after gaining around 5% on Wednesday.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) shares fell 6.4% to $15.41 in pre-market trading.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) shares fell 5.4% to $4.22 in pre-market trading following downbeat third-quarter results. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

BEKE

CAPR

LILM

MNSO

PRQR

CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock increased by 189.2% to $0.94 during Wednesday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 21.72% to $0.68. The company's market cap stands at $14.5 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 12.23% to $1.0. The market value of their outstanding shares is at $5.7 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares moved upwards by 5.9% to $6.99. The market value of their outstanding shares is at $130.3 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock rose 5.17% to $18.5. The company's market cap stands at $117.3 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) shares moved upwards by 5.08% to $1.24. The company's market cap stands at $88.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares fell 14.8% to $0.54 during Wednesday's after-market session. The company's market cap stands at $20.4 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 12.74% to $7.33. The market value of their outstanding shares is at $106.4 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock decreased by 11.07% to $18.24. The company's market cap stands at $644.5 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 10.98% to $5.76. The company's market cap stands at $5.9 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 10.4% to $0.56. The company's market cap stands at $11.7 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined by 9.45% to $1.63. The market value of their outstanding shares is at $302.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASMB

CHRO

CTCX

HCWB

KLTO

NVCT

OVID

12 Health Care Stocks Moving In Wednesday's After-Market Session

Cerus shares are trading lower after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.

CE Mark review has been concluded without approval; assessing strategy for anticipated future filing in Europe.

Cerus Updates On INTERCEPT RBC Programs In US And Europe; To Now Receive Additional Support From BARDA Through New Contract Valued At Up To $248M

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) rose sharply in <a href="https://www.benzinga.com/quote/LBPH">today's pre-market trading</a>.
Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2.6 billion equity value.
Longboard Pharmaceuticals shares jumped 46.8% to $57.13 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Inventiva S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NYSE">IVA</a>) rose 86.2% to $3.52 in pre-market trading. The company raised up to €348 million to fund Phase 3 NATiV3 clinical trial for MASH, and named new chairman and director.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 92.2% to $0.7297 in pre-market trading. Tevogen Bio announced plans to share $1 billion+ revenue potential of its pipeline portfolio beginning week of Oct. 14.</li>
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares rose 72% to $4.1100 in pre-market trading after gaining 4% on Friday.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares surged 15% to $2.32 in pre-market trading after declining over 12% on Friday.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) gained 15% to $11.50 in pre-market trading.</li>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) rose 14.3% to $5.02 in pre-market trading after declining 3% on Friday.</li>
<li>Argo Blockchain plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) shares jumped 12.4% to $1.27 in pre-market trading after gaining around 8% on Friday.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) climbed 9.3% to $1.99 in pre-market trading following a 5% gain on Friday.</li>
<li>Blend Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NASDAQ">BLND</a>) gained 7.7% to $3.92 in pre-market trading after gaining 3% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares dipped 76.8% to $0.3401 in pre-market trading as the company's board of directors approved the liquidation and wind-up of the company.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) shares fell 70.7% to $0.0765 in pre-market trading after gaining around 8% on Friday.</li>
<li>Vicinity Motor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) fell 44.1% to $0.0655 in today's pre-market trading. Vicinity Motor failed to renegotiate terms with creditors and concluded workout plan without restructuring.</li>
<li>Notable Labs, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTBL#NASDAQ">NTBL</a>) fell 25.8% to $0.2896 in pre-market trading.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) shares declined 22.4% to $5.54 in pre-market trading after surging 238% on Friday.</li>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) shares declined 18.8% to $0.39 in pre-market trading after gaining 17% on Friday. SIMPPLE, last week, announced new contracts and partnerships in Australia and New Zealand.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 17.1% to $0.8125 in pre-market trading after surging 63% on Friday.</li>
<li>Innovation Beverage Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBG#NASDAQ">IBG</a>) shares fell 15% to $0.8501 after declining 5% on Friday.</li>
<li>BAIYU Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYU#NASDAQ">BYU</a>) declined 13.3% to $0.26 in pre-market trading after declining 35% on Friday.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) fell 6.6% to $1.85 in pre-market trading after jumping around 28% on Friday.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41308141/this-analyst-with-85-accuracy-rate-sees-around-20-upside-in-amd-here-are-5-stock-picks-for-last-week"> This Analyst With 85% Accuracy Rate Sees Around 20% Upside In AMD &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

ARBK

BLND

DXYZ

LBPH

NIVF

NTBL

PACB

RANI

RILY

SPPL

XPON

ZPTA

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket

<a href="https://sam.gov/opp/dd5785c70ab7460c970270efb9eef18c/view" title="https://sam.gov/opp/dd5785c70ab7460c970270efb9eef18c/view">https://sam.gov/opp/dd5785c70ab7460c970270efb9eef18c/view</a>

Contracts

Cerus Corp Awarded $248,591,407.65 Biomedical Advanced Research and Development Authority Contract From The Department Of Human Services For Health R&D Services; Health Care Services; Experimental Development

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Tuesday.
Shares of ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) shares declined 15.2% to $8.31 in pre-market trading after the company reported worse-than-expected financial results for the second quarter and <a href="https://www.benzinga.com/news/24/08/40173882/zoominfo-technologies-q2-earnings-revenue-miss-eps-miss-soft-guidance-cfo-transition-and-more">announced a management transition</a>.
The company announced that CFO Cameron Hyzer will step down from his role. Hyzer will remain in an advisory capacity until Oct. 7 to help facilitate a smooth transition. Graham O&#8217;Brien has been named interim CFO, effective Sept. 6.
ZoomInfo Technologies shares dipped 15.2% to $8.31 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Chegg Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares declined 18.7% to $2.38 in pre-market trading following second-quarter results.</li>
<li>Helport AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPAI#NASDAQ">HPAI</a>) shares fell 15.2% to $7.15 in pre-market trading after declining 24% on Monday.</li>
<li>Sumitomo Mitsui Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMFG#NYSE">SMFG</a>) fell 10.5% to $10.80 in pre-market trading after declining around 4% on Monday.</li>
<li>Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) shares declined 8% to $26.83 in pre-market trading following weak quarterly sales.</li>
<li>Mizuho Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFG#NYSE">MFG</a>) fell 7% to $3.57 in pre-market trading after declining over 5% on Monday.</li>
<li>Mitsubishi UFJ Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>) shares declined 5.6% to $8.96 in pre-market trading.</li>
<li>Cerus Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) fell 4.5% to $2.12 in pre-market trading following a 5% decline on Monday.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) shares slipped 3.6% to $57.78. Sea will announce its second quarter results before the opening bell on Aug. 13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40178833/dow-records-worst-day-in-around-2-years-mag-7-stocks-lose-650b-in-market-capitalization-greed-index">Dow Records Worst Day In Around 2 Years, Mag 7 Stocks Lose $650B In Market Capitalization: Greed Index Moves To &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

CHGG

HPAI

MUFG

SMFG

ZoomInfo Reports Weak Results, Joins Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stocks were lower, with the Dow Jones index falling over 900 points on Friday.
Shares of MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) rose sharply during Friday's session after the company reported better-than-expected quarterly financial results.
Mercado Libre reported net revenue of $5.07 billion in the second quarter, up 42% year-over-year. The revenue beat a Street consensus estimate of $4.68 billion, according to data from Benzinga Pro.
The company reported a 36% year-over-year increase in total payment volume for the second quarter and a 20% year-over-year rise in gross merchandise volume. Earnings per share were $10.48 in the second quarter, beating a Street consensus estimate of $8.43.
MercadoLibre shares jumped 9.6% to $1,760.79 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) gained 26% to $24.50.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares surged 23.6% to $43.52 in pre-market trading following better-than-expected second-quarter earnings and strong guidance.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) gained 23% to $2.5200  after the company reported better-than-expected second-quarter EPS results and raised its FY24 product revenue guidance above estimates..</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) shares gained 14.9% to $11.38 after the company reported better-than-expected quarterly financial results and issued FY24 revenue guidance above estimates.</li>
<li>Willdan Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) climbed 10.1% to $36.52 after the company reported better-than-expected second-quarter financial results.</li>
<li>Fresh Del Monte Produce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) gained 8.6% to $26.73 following better-than-expected earnings.</li>
<li>ICF International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) rose 8.3% to $158.06 following upbeat quarterly results.</li>
<li>EZCORP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) jumped 8.2% to $11.35.</li>
<li>Standard BioTools Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NYSE">LAB</a>) gained 7.7% to $1.530.</li>
<li>Bright Horizons Family Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) gained 7.5% to $127.32 following strong quarterly results.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) rose 6.7% to $115.52 as the company posted upbeat earnings.</li>
<li>GoDaddy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) jumped 5.8% to $149.66 after the company reported better-than-expected second-quarter sales results..</li>
<li>The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) gained 4.3% to $139.94 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 adjusted EPS guidance above estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40131885/dow-dips-over-400-points-apple-posts-upbeat-earnings">Dow Dips Over 400 Points; Apple Posts Upbeat Earnings</a></li>
</ul>

BFAM

DASH

EZPW

FTEL

GDDY

ICFI

MELI

TNDM

WLDN

MercadoLibre Posts Upbeat Results, Joins Integral Ad Science, Willdan Group, Fresh Del Monte Produce And Other Big Stocks Moving Higher On Friday

Cerus shares are trading higher after the company reported better-than-expected Q2 EPS results and raised its FY24 product revenue guidance above estimates.

Wall Street favors small caps for their high growth potential, broad sector exposure, and strong performance during economic recoveries, especially as rate cuts lower borrowing costs. Hence, it may be wise to consider buying high-potential small-cap stocks: Owens & Minor (OMI), Orion (OEC), and Cerus (CERS). Read on... Small-cap stocks benefit greatly from lower interest rates, as they typically carry higher debt levels than large-cap companies. Moreover, small-cap stocks offer diverse industry exposure beyond tech, including in medical, biotech, and chemical industries, providing growth potential across multiple sectors.
Therefore, for investors seeking high-upside opportunities, fundamentally strong small-cap stocks like Owens &amp; Minor, Inc. (<a href="https://stocknews.com/stock/OMI/">OMI</a>), Orion S.A. (<a href="https://stocknews.com/stock/OEC/">OEC</a>), and Cerus Corporation (<a href="https://stocknews.com/stock/CERS/">CERS</a>) are worth considering.
Historically, small-cap stocks have outperformed large caps during economic recoveries. As inflation stabilizes and if the economy strengthens, small-cap stocks could benefit significantly. Small-cap stocks offer broad sector exposure, which helps reduce regulatory and sector-specific risks while providing diverse investment opportunities.
With inflation currently at <a href="https://www.reuters.com/markets/rates-bonds/traders-stick-bets-25-bps-fed-rate-cuts-nov-dec-2024-10-31/">2.1%</a>, just above the Fed's target, rate cuts are anticipated in December. These cuts could reduce borrowing costs, stimulate consumer spending, and boost small-cap stock valuations. Alongside, the U.S. economy expanded by an annualized <a href="https://www.conference-board.org/brief/global-economy/gdp-q3-2024">2.8% in the third quarter</a>, highlighting further optimism for the small caps.
Furthermore, small-cap stocks often yield higher returns in volatile markets due to increased investor demand for growth-oriented opportunities. Considering these conducive trends, let's examine the fundamentals of the above-mentioned small-cap stocks.
Owens &amp; Minor, Inc. (<a href="https://stocknews.com/stock/OMI/">OMI</a>)
Valued at $1.03 billion by market cap, OMI, along with its subsidiaries, operates as a healthcare solutions company worldwide. It functions through two segments: Products &amp; Healthcare Services and Patient Direct.
On September 10, 2024, OMI announced a partnership with Google Cloud to enhance its QSight clinical inventory management system. This collaboration aims to improve inventory optimization for hospitals, leveraging Google Cloud's AI capabilities for real-time insights and predictive management.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, OMI's 3.12% is 22.5% higher than the 2.55% industry average. Its 4.29% trailing-12-month levered FCF margin is 150.4% higher than the 1.71% industry average. Likewise, the stock's 1.99x trailing-12-month asset turnover ratio is 384.8% higher than the 0.41x industry average.
OMI's revenue for the fiscal second quarter ended June 30, 2024, increased 4.2% year-over-year to $2.67 billion. Its non-GAAP operating income was $76.26 million, up 23% year-over-year. Additionally, the company's non-GAAP net income and non-GAAP net income per common share were $28.15 million and $0.36, respectively, up 98% and 100% over the prior-year quarter.
For the quarter ended September 30, 2024, OMI's revenue is expected to grow 3.4% year-over-year to $2.68 billion. Its EPS for the quarter ending March 31, 2025, is expected to rise 38.4% year-over-year to $0.26. It surpassed the Street EPS estimates in each of the trailing four quarters.
Over the past month, OMI's stock has declined 8.2% to close the last trading session at $13.36. The average analyst price target of $20 indicates a <a href="https://www.tipranks.com/stocks/omi/forecast">49.7% upside potential</a>.
OMI's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect an optimistic outlook. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has a B grade for Growth and Value. It is ranked #53 out of 138 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. To see OMI's Momentum, Stability, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/OMI/">click here</a>.
Orion S.A. (<a href="https://stocknews.com/stock/OEC/">OEC</a>)
Valued at $898.69 million by market cap, Headquartered in Senningerberg, Luxembourg, OEC engages in the manufacture and sale of carbon black products. It operates through two segments: Specialty Carbon Black and Rubber Carbon Black.
In terms of the trailing-12-month Capex / Sales, OEC's 10% is 28.9% higher than the 7.76% industry average. Its 16.18% trailing-12-month Return on Common Equity is 185.8% higher than the 5.66% industry average. Also, the stock's 7.43% trailing-12-month Return on Total Capital is 52.3% higher than the 4.88% industry average.
During the fiscal second quarter ended June 30, 2024, OEC's net sales rose 4% year-over-year to $477 million. Its operating income was $109.80 million. Similarly, the company's adjusted net income and adjusted EPS were $24.50 million and $0.41, respectively.
Street expects OEC's revenue for the quarter ended September 30, 2024, to increase 3.1% year-over-year to $480.67 million. Its EPS for the quarter ending December 31, 2024, is expected to rise 143.9% year-over-year to $0.41. OEC's stock has declined 11.2% over the past year to close the last trading session at $15.40. The average analyst price target of $22 indicates a <a href="https://www.tipranks.com/stocks/semr/forecast">42.1% upside potential</a>.
OEC's strong fundamentals are reflected in its POWR Ratings. It has a B grade for Value. It is ranked #38 out of 80 stocks in the B-rated <a href="https://stocknews.com/category/chemicals/">Chemicals</a> industry. Beyond what we stated above, we also have given OEC grades for Growth, Momentum, Stability, Sentiment, and Quality. Get all the OEC ratings <a href="https://stocknews.com/stock/OEC/">here</a>.
Cerus Corporation (<a href="https://stocknews.com/stock/CERS/">CERS</a>)
Valued at $282.29 million by market cap, CERS operates as a biomedical products company, focusing on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
In terms of the trailing-12-month asset turnover ratio, CERS' 0.89x is 117.3% higher than the 0.41x industry average.
CERS's total revenue for the fiscal third quarter ended September 30, 2024, increased 7.2% year-over-year to $50.66 million. Its adjusted EBITDA was $4.39 million, compared to an adjusted EBITDA loss of $972 thousand in the prior-year quarter. Additionally, the company's gross profit on product revenue was $26.20 million, up 20.1% from the year-ago value.
Analysts expect CERS' revenue for the quarter ending December 31, 2024, to increase 8.4% year-over-year to $50.69 million. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, CERS' stock has gained 14.5% to close the last trading session at $1.58. The average analyst price target of $4 indicates a <a href="https://www.tipranks.com/stocks/semr/forecast">151.6% upside potential</a>.
CERS' POWR Ratings reflect its solid prospects. CERS has a B grade for Sentiment. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #121 out of 328 stocks. To access CERS' additional ratings for Growth, Value, Momentum, Stability, and Quality, <a href="https://stocknews.com/stock/CERS/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
OMI shares rose $1.00 (+8.33%) in after-hours trading Monday. Year-to-date, OMI has declined -37.73%, versus a 21.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/omi-oec-cers-3-high-potential-small-cap-stocks-wall-street-loves/>3 High-Potential Small-Cap Stocks Wall Street Loves</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Potential Small-Cap Stocks Wall Street Loves

ARKK's holdings ranked by SA Quant Grades

Tracking Baker Brothers Portfolio - Q3 2024 Update

"We are pleased with our strong performance, which contributed to continued double-digit product revenue growth for the full year 2024, driven by s...

Cerus raises FY24 revenue view to $180.3M from $177M-$179M, consensus $186.18M

"With our strong preliminary top-line results, we continue to strengthen our financial position to support future growth initiatives," Greenman add...

Cerus sees FY25 revenue $194M-$200M, consensus $206.33M

Cerus expects prelim FY 2024 product revenue to be $180.3M

Analyst Mathew Blackman of Stifel Nicolaus maintained a Buy rating on Cerus (CERS – Research Report), retaining the price target of $3.00. Mathew B...

Comments

Cerus

뉴스

에 대한 최신 뉴스 Cerus (NASDAQ:CERS) 주식

화요일, 10월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌